High-Throughput Antibody Production Revolutionizes Therapeutic Development
Table of Contents
A free webinar will explore how recent advances in high-throughput recombinant production are reshaping antibody discovery strategies, offering a pathway to faster, more cost-effective, and ethical therapeutic development.
The landscape of therapeutic antibody development is undergoing a significant transformation, driven by innovations in high-throughput recombinant production (HTP). These advancements are enabling researchers to overcome longstanding challenges and accelerate the creation of next-generation treatments and diagnostics. According to a company release, improved expression platforms – characterized by smaller volumes, automation, increased capacity, and serial production – are yielding higher antibody yields at substantially reduced costs.
Expanding the Antibody Pipeline with HTP
Traditionally, antibody development involved a lengthy and expensive process of generating and evaluating a limited number of candidates. This often led to premature narrowing of options, potentially overlooking promising leads. HTP production changes this paradigm. By facilitating the generation and evaluation of broader antibody panels simultaneously, researchers can now explore a wider range of possibilities.
“Producing large numbers of variants has become critical for testing different formats and engineering strategies,” one analyst noted, emphasizing the importance of this expanded testing capacity. This allows for optimization of key antibody characteristics, including developability, immunogenicity, and solubility.
AI and Animal-Free Research Fuel Innovation
The integration of new technologies, such as artificial intelligence (AI), is further amplifying the impact of HTP. AI-driven analysis enables the systematic optimization of a greater number of molecules, increasing the likelihood of identifying clinically relevant antibodies with superior characteristics.
Beyond efficiency gains, these advancements are also promoting more ethical research practices. A key benefit of HTP is the potential to reduce reliance on animal testing, a growing priority within the therapeutic development community. By enabling more robust in vitro and in silico assessments, researchers can minimize the need for animal models.
Webinar Details: Driving Success in Therapeutics
The upcoming webinar, “Driving Success in Therapeutics with Recombinant Antibody Production,” will delve into the specifics of these transformative technologies. Nataliia Aleksandrova, Head of Bioproduction Service at ProteoGenix, will lead the live session on Tuesday, November 4, 2025, at 11am EST (5pm CET/EU-Central). The discussion will cover how HTP platforms are reshaping discovery workflows, the influence of production system selection on performance, and the acceleration of development timelines through recombinant strategies.
Interested parties can register for the webinar and find more information at Driving Success in Therapeutics with Recombinant Antibody Production.
Xtalks: A Leading Provider of Life Science Education
The webinar is hosted by Xtalks, a leading provider of educational webinars and digital content for the global life science, food, healthcare, and medical device communities. Xtalks connects industry professionals with valuable insights from thought leaders and service providers, helping them stay abreast of the latest developments and regulations. More information about Xtalks can be found at www.xtalks.com. For inquiries about hosting a webinar, visit www.xtalks.com/why-host-a-webinar/. Contact Vera Kovacevic at +1 (416) 977-6555 x371 or [email protected] for further details.
